Diabetes drug gets good pre-clinical results, speeds approval process
Biocure Med has confirmed positive results from the pre-clinical diabetes treatment of its proprietary product DiaCure.

The DiaCure therapy was developed to treat both type 1 and type 2 diabetes patients, according the Praekasa Mueng, Thailand-based Biocure. The natural component of the DiaCure formula allows the patient to not only stabilize their sugar level but also lose weight and suppress their psychological need or urge for sugar, the company said. It also stimulates the pancreas and can replace, in most cases, the insulin injections or conventional oral drugs, such as Diabeta and others, Biocure reported.

The new breakthrough for DiaCure in the treatment of diabetes will accelerate its manufacturing and distribution process, and the management team has decided to file all requisite documentation to obtain a natural product number from the Canadian Health Care Department, according to Alan Rossy, PhD, senior vice president, R&D and project management at Biocure.